Drug Trial Radar · NCT06402201
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
May 24, 2024
Primary completion
Dec 30, 2026
Study completion Apr 5, 2027
Sponsor
- Lead sponsor
- CDR-Life AGIndustry
- Sponsor type
- Industry
- First posted
- May 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A\*02:01 tissue marker and whose cancer is positive for MAGE-A4.
Conditions
- Select Advanced Solid Tumors
Interventions
CDR404Biological
IV infusions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of dose limiting toxicities (DLTs)Time frame: From first dose to DLT period (21 days)
- Incidence and severity of (serious) adverse events ([S]AEs)Time frame: From first dose to 90 days after the last dose
- Anti-tumor response: Overall Response Rate (ORR)Time frame: From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
Locations
18 sites in 6 countries. Site status is shown where the registry gives one.
Providence Cancer Institute
Portland, Oregon
Pennsylvania Hospital
Philadelphia, Pennsylvania
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium
Institut Jules Bordet
Brussels, Belgium
Cliniques Universitaires Saint-Luc, UCL Ouvain
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Rigshospitalet
Copenhagen, Denmark
Istituto Clinico Humanitas
Milan, Italy
Isituto Europeo di Oncologia (IEO)
Milan, Italy
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Institut Catala d'Oncologia, L'Hospitalet de Llobregat (ICO)
Barcelona, Spain
Hospital 12 de Octubre
Madrid, Spain
START Madrid
Madrid, Spain
Hospital Universitari i Politecnic La Fe
Valencia, Spain
Instituto de Investigacion Sanitaria (INCLIVA)
Valencia, Spain
The Beatson West of Scotland Cancer Center
Glasgow, United Kingdom
Guys and St Thomas' NHS Foundation Trust
London, United Kingdom
Royal Marsden Hospital
Sutton, London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.